The inside story at Allergan is now firmly public, as the company’s plans to divest itself of certain product categories and acquire another firm were confirmed over the weekend. What was rumored has become fact This weekend Allergan publicly confirmed it will shed the firm’s generic-drug business to Teva Pharmaceuticals for $40.5 billion and the company will purchase Naurex, a developer of antidepressant drugs, for $560 million. On July 22 ValueWalk reported on a secret meeting that discussed a sales and marketing integration and aggressive acquisition strategy, citing unnamed sources. Then on July 24, Bloomberg reported Allergan was planning on…
Buy The Rumor: Allergan Goes Public on Divestiture, Acquisition Plans
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.